Selected research
Industry Research
Systemic Mastocytosis Treatment Industry Research Report 2026
Market perspective
The global Systemic Mastocytosis Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Systemic Mastocytosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Systemic Mastocytosis Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Systemic Mastocytosis Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Systemic Mastocytosis Treatment include Novartis AG, AbbVie Inc, Stemline Therapeutics Inc, Seattle Genetics Inc, Patara Pharma Inc, Deciphera Pharmaceuticals LLC, Bristol-Myers Squibb Company, Blueprint Medicines Corp and Arog Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Systemic Mastocytosis Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Systemic Mastocytosis Treatment Market by Company
Novartis AG
AbbVie Inc
Stemline Therapeutics Inc
Seattle Genetics Inc
Patara Pharma Inc
Deciphera Pharmaceuticals LLC
Bristol-Myers Squibb Company
Blueprint Medicines Corp
Arog Pharmaceuticals Inc
AB Science SA
Systemic Mastocytosis Treatment Segment by Type
Cromolyn Sodium
Brentuximab Vedotin
Crenolanib Besylate
BLU-285
AK-002
Others
Systemic Mastocytosis Treatment Segment by Application
Homecare
Hospital
Clinic
Systemic Mastocytosis Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Systemic Mastocytosis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Systemic Mastocytosis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Systemic Mastocytosis Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Systemic Mastocytosis Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Systemic Mastocytosis Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Systemic Mastocytosis Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cromolyn Sodium
- Brentuximab Vedotin
- Crenolanib Besylate
- BLU-285
- AK-002
- Others
Applications
- Homecare
- Hospital
- Clinic
Companies covered
- Novartis AG
- AbbVie Inc
- Stemline Therapeutics Inc
- Seattle Genetics Inc
- Patara Pharma Inc
- Deciphera Pharmaceuticals LLC
- Bristol-Myers Squibb Company
- Blueprint Medicines Corp
- Arog Pharmaceuticals Inc
- AB Science SA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Systemic Mastocytosis Treatment Market Size (2021-2032)
- 2.2.2 Global Systemic Mastocytosis Treatment Sales (2021-2032)
- 2.2.3 Global Systemic Mastocytosis Treatment Market Average Price (2021-2032)
- 2.3 Systemic Mastocytosis Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Cromolyn Sodium
- 2.3.3 Brentuximab Vedotin
- 2.3.4 Crenolanib Besylate
- 2.3.5 BLU-285
- 2.3.6 AK-002
- 2.3.7 Others
- 2.4 Systemic Mastocytosis Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Homecare
- 2.4.3 Hospital
- 2.4.4 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Systemic Mastocytosis Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Systemic Mastocytosis Treatment Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Systemic Mastocytosis Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Systemic Mastocytosis Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Systemic Mastocytosis Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Systemic Mastocytosis Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Systemic Mastocytosis Treatment, Product Type & Application
- 3.8 Global Manufacturers of Systemic Mastocytosis Treatment, Established Date
- 3.9 Global Systemic Mastocytosis Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Systemic Mastocytosis Treatment Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 AbbVie Inc
- 4.2.1 AbbVie Inc Company Information
- 4.2.2 AbbVie Inc Business Overview
- 4.2.3 AbbVie Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AbbVie Inc Systemic Mastocytosis Treatment Product Portfolio
- 4.2.5 AbbVie Inc Recent Developments
- 4.3 Stemline Therapeutics Inc
- 4.3.1 Stemline Therapeutics Inc Company Information
- 4.3.2 Stemline Therapeutics Inc Business Overview
- 4.3.3 Stemline Therapeutics Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Stemline Therapeutics Inc Systemic Mastocytosis Treatment Product Portfolio
- 4.3.5 Stemline Therapeutics Inc Recent Developments
- 4.4 Seattle Genetics Inc
- 4.4.1 Seattle Genetics Inc Company Information
- 4.4.2 Seattle Genetics Inc Business Overview
- 4.4.3 Seattle Genetics Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Seattle Genetics Inc Systemic Mastocytosis Treatment Product Portfolio
- 4.4.5 Seattle Genetics Inc Recent Developments
- 4.5 Patara Pharma Inc
- 4.5.1 Patara Pharma Inc Company Information
- 4.5.2 Patara Pharma Inc Business Overview
- 4.5.3 Patara Pharma Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Patara Pharma Inc Systemic Mastocytosis Treatment Product Portfolio
- 4.5.5 Patara Pharma Inc Recent Developments
- 4.6 Deciphera Pharmaceuticals LLC
- 4.6.1 Deciphera Pharmaceuticals LLC Company Information
- 4.6.2 Deciphera Pharmaceuticals LLC Business Overview
- 4.6.3 Deciphera Pharmaceuticals LLC Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Deciphera Pharmaceuticals LLC Systemic Mastocytosis Treatment Product Portfolio
- 4.6.5 Deciphera Pharmaceuticals LLC Recent Developments
- 4.7 Bristol-Myers Squibb Company
- 4.7.1 Bristol-Myers Squibb Company Company Information
- 4.7.2 Bristol-Myers Squibb Company Business Overview
- 4.7.3 Bristol-Myers Squibb Company Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bristol-Myers Squibb Company Systemic Mastocytosis Treatment Product Portfolio
- 4.7.5 Bristol-Myers Squibb Company Recent Developments
- 4.8 Blueprint Medicines Corp
- 4.8.1 Blueprint Medicines Corp Company Information
- 4.8.2 Blueprint Medicines Corp Business Overview
- 4.8.3 Blueprint Medicines Corp Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Blueprint Medicines Corp Systemic Mastocytosis Treatment Product Portfolio
- 4.8.5 Blueprint Medicines Corp Recent Developments
- 4.9 Arog Pharmaceuticals Inc
- 4.9.1 Arog Pharmaceuticals Inc Company Information
- 4.9.2 Arog Pharmaceuticals Inc Business Overview
- 4.9.3 Arog Pharmaceuticals Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Arog Pharmaceuticals Inc Systemic Mastocytosis Treatment Product Portfolio
- 4.9.5 Arog Pharmaceuticals Inc Recent Developments
- 4.10 AB Science SA
- 4.10.1 AB Science SA Company Information
- 4.10.2 AB Science SA Business Overview
- 4.10.3 AB Science SA Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AB Science SA Systemic Mastocytosis Treatment Product Portfolio
- 4.10.5 AB Science SA Recent Developments
5 Global Systemic Mastocytosis Treatment Market Scenario by Region
- 5.1 Global Systemic Mastocytosis Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Systemic Mastocytosis Treatment Sales by Region: 2021-2032
- 5.2.1 Global Systemic Mastocytosis Treatment Sales by Region: 2021-2026
- 5.2.2 Global Systemic Mastocytosis Treatment Sales by Region: 2027-2032
- 5.3 Global Systemic Mastocytosis Treatment Revenue by Region: 2021-2032
- 5.3.1 Global Systemic Mastocytosis Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Systemic Mastocytosis Treatment Revenue by Region: 2027-2032
- 5.4 North America Systemic Mastocytosis Treatment Market Facts & Figures by Country
- 5.4.1 North America Systemic Mastocytosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Systemic Mastocytosis Treatment Sales by Country (2021-2032)
- 5.4.3 North America Systemic Mastocytosis Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Systemic Mastocytosis Treatment Market Facts & Figures by Country
- 5.5.1 Europe Systemic Mastocytosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Systemic Mastocytosis Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Systemic Mastocytosis Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Systemic Mastocytosis Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific Systemic Mastocytosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Systemic Mastocytosis Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Systemic Mastocytosis Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Systemic Mastocytosis Treatment Market Facts & Figures by Country
- 5.7.1 South America Systemic Mastocytosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Systemic Mastocytosis Treatment Sales by Country (2021-2032)
- 5.7.3 South America Systemic Mastocytosis Treatment Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Systemic Mastocytosis Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Systemic Mastocytosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Systemic Mastocytosis Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Systemic Mastocytosis Treatment Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Systemic Mastocytosis Treatment Sales by Type (2021-2032)
- 6.1.1 Global Systemic Mastocytosis Treatment Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Systemic Mastocytosis Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global Systemic Mastocytosis Treatment Revenue by Type (2021-2032)
- 6.2.1 Global Systemic Mastocytosis Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Systemic Mastocytosis Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global Systemic Mastocytosis Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Systemic Mastocytosis Treatment Sales by Application (2021-2032)
- 7.1.1 Global Systemic Mastocytosis Treatment Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Systemic Mastocytosis Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global Systemic Mastocytosis Treatment Revenue by Application (2021-2032)
- 7.2.1 Global Systemic Mastocytosis Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Systemic Mastocytosis Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global Systemic Mastocytosis Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Systemic Mastocytosis Treatment Value Chain Analysis
- 8.1.1 Systemic Mastocytosis Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Systemic Mastocytosis Treatment Production Mode & Process
- 8.2 Systemic Mastocytosis Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Systemic Mastocytosis Treatment Distributors
- 8.2.3 Systemic Mastocytosis Treatment Customers
9 Global Systemic Mastocytosis Treatment Analyzing Market Dynamics
- 9.1 Systemic Mastocytosis Treatment Industry Trends
- 9.2 Systemic Mastocytosis Treatment Industry Drivers
- 9.3 Systemic Mastocytosis Treatment Industry Opportunities and Challenges
- 9.4 Systemic Mastocytosis Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst